谷歌浏览器插件
订阅小程序
在清言上使用

Abstract CT250: A Phase 1a/1b, Open-Label First-in-human Study of the Safety, Tolerability, and Feasibility of Gene-Edited Autologous NeoTCR-T Cells (Neotcr-P1) Administered to Patients with Locally Advanced or Metastatic Solid Tumors

Cancer Research(2020)

引用 0|浏览21
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要